Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.

Industry News Archives

Tafasitamab-cxix Speaker Program

Tafasitamab-cxix (Monjuvi®, Incyte), in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Join a one-hour webcast to learn more about the usage of Tafasitamab-cxix (Monjuvi®) in treating your patients. For more information, click here

Posted on 10/06/2020

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us